Abstracts tagged "gout"

Abstract Number: L05 • ACR Convergence 2024
Prolonged Plasma Urate-Lowering After a Single Intravenous Administration of PRX-115, a Novel PEGylated Uricase, in Participants with Elevated Urate Levels
Christian Schwabe¹, Orit Cohen Barak², Alexandra Cole³, Hadar Reuveni², Liron Shelev², Liora Blinder-Haddad² and Nicola Dalbeth⁴, ¹NZCR, Auckland, New Zealand, ²Protalix Ltd, Karmiel, Israel, ³NZCR, Christchurch, New Zealand, ⁴University of Auckland, Auckland, New Zealand
Background/Purpose: PEGylated uricases have already demonstrated therapeutic modality in the treatment of refractory gout patients. PRX-115 is a recombinant homotetrameric uricase enzyme, produced from Candida…
Abstract Number: 0279 • ACR Convergence 2024
Macrophage Intracellular Fates of Monosodium Urate and Calcium Pyrophosphate Crystals: Phagocytosis, Exchanged/expulsion and Dissolution of Crystals
Charles Leroy¹, Nghia Pham², François Brial³, Brenda Kischkel⁴, gwénaêlle Jayat⁵, Elena Ishow⁶, Christèle Combes⁷, Leo Joosten⁴, Augustin Latourte⁸, Pascal Richette⁹ and Hang-Korng Ea¹⁰, ¹Inserm 1132 / Université Paris Cité, levallois-perret, France, ²INSERM 1132, BIOSCAR, Lariboisière hospital, Paris, France, ³Inserm 1132/ Université Paris Cité, Paris, France, ⁴Radboudumc, Nijmegen, Netherlands, ⁵Université Paris cité / Inserm 1132, paris, France, ⁶Université de Nantes / Ceisam, Nantes, France, ⁷INP-ENSIACET, Toulouse, France, ⁸AP-HP, Paris, France, ⁹Lariboisière Hospital, Paris, France, ¹⁰Université Paris Cité, INSERM UMR 1132 BIOSCAR, Paris, France
Background/Purpose: Gout, due to the presence of monosodium urate crystals (MSU) and calcium pyrophosphate (CPP) crystal deposition disease are both responsible for recurrent inflammation flares.…
Abstract Number: 1085 • ACR Convergence 2024
Pharmacokinetics and Pharmacodynamics of Tigulixostat in Participants with Mild, Moderate, and Severe Renal Impairment
Ashish Kumar¹, Ali Hariri¹, Yunjung Lee² and Minhyung Lee², ¹LG Chem Life Sciences USA, Boston, MA, ²LG Chem, Seoul, Republic of Korea
Background/Purpose: Tigulixostat is a potent and highly selective non-purine based xanthine oxidase inhibitor (XOi) being investigated for the management of hyperuricemia in patients with gout.…
Abstract Number: 1103 • ACR Convergence 2024
The Role of Renal Dual-Energy CT in Exploring the Gouty Kidney: The RENODECT Study
Tristan Pascart¹, Elie Dauphin¹, Chio Yokose², Charlotte Jauffret³, Hyon K. Choi⁴ and Jean-François Budzik⁵, ¹Université Catholique de Lille, Lille, Nord-Pas-de-Calais, France, ²Massachusetts General Hospital, Boston, MA, ³Lille Catholic University, Lille, Nord-Pas-de-Calais, France, ⁴Massachusetts General Hospital, Lexington, MA, ⁵Lille Catholic University, Lille, France
Background/Purpose: Chronic kidney disease (CKD) is a common feature in gout, and can have multiple causes, some of which are gout specific, such as gout…
Abstract Number: 2010 • ACR Convergence 2024
The Influence of Treat-to-target Urate Lowering Therapy and Anti-inflammatory Prophylaxis on Circulating Measures of Inflammation in Gout
Austin Wheeler¹, Tanner Ourada², Michael Duryee¹, Bryant England¹, Richard Reynolds³, James O'Dell¹, Jeff Newcomb¹, Michael Pillinger⁴, Robert Terkeltaub⁵, Ryan Ferguson⁶, Mary Brophy⁶, Tony Merriman⁷ and Ted Mikuls¹, ¹University of Nebraska Medical Center, Omaha, NE, ²University of Nebraska-Medical Center: College of Medicine, Omaha, NE, ³University of Alabama at Birmingham, Birmingham, AL, ⁴New York University Grossman School of Medicine, New York,, NY, ⁵Retired, San Diego, CA, ⁶Veterans Affairs, Boston, MA, ⁷University of Alabama at Birmingham, Homewood, AL
Background/Purpose: Gout is the most common inflammatory arthritis worldwide and is associated with substantial cardiometabolic morbidity and mortality. In the STOP Gout trial (O’Dell JR…
Abstract Number: 2557 • ACR Convergence 2024
The Relation of Colchicine to Knee/hip Replacement Among People with Gout in a Population-based Cohort Study
Zhiqiang Wang¹, Sarah Tilley², Christine Peloquin², Eva Petrow³, Margaret Clancy² and Tuhina Neogi², ¹Clinical Research Centre, Zhujiang Hospital, Southern Medical University, Guangzhou, China, Guangzhou, Guangdong, China (People's Republic), ²Boston University Chobanian & Avedisian School of Medicine, Boston, MA, ³Boston Medical Center, Boston, MA
Background/Purpose: Colchicine, an anti-inflammatory drug commonly used in gout, has been associated with a lower incidence of total knee/hip replacement compared to placebo among participants…
Abstract Number: 0280 • ACR Convergence 2024
Trends in Management and Consultations for Gout: A Study of 18 Million Adults Using the OpenSAFELY Platform
Mark Russell¹, Jon Massey², Edward Roddy³, Brian MacKenna⁴, Seb Bacon⁴, Ben Goldacre⁴, Colm Andrews⁴, George Hickman⁴, Amir Mehrkar², Arti Mahto⁵, Andrew Rutherford⁶, Samir Patel¹, Maryam Adas⁷, Edward Alveyn⁷, deepak Nagra¹, Katie Bechman⁷, Joanna Ledingham⁸, Joanna Hudson⁹, Sam Norton¹, Andrew Cope⁷ and James Galloway¹⁰, ¹King's College London, London, England, United Kingdom, ²University of Oxford, Oxford, England, United Kingdom, ³Keele University, Keele, England, United Kingdom, ⁴University of Oxford, Oxford, United Kingdom, ⁵King's College Hospital NHS Foundation Trust, London, United Kingdom, ⁶King's College Hospital NHS Foundation Trust, London, England, United Kingdom, ⁷King's College London, London, United Kingdom, ⁸Portsmouth Hospitals University NHS Trust, Portsmouth, United Kingdom, ⁹King's College London, King's College London, United Kingdom, ¹⁰Centre for Rheumatic Diseases, King's College London, London, United Kingdom
Background/Purpose: Data from before the COVID-19 pandemic had shown persistently poor care for people with gout in many countries worldwide. Whether this was further exacerbated…
Abstract Number: 1086 • ACR Convergence 2024
Risk Factors Associated with Loss to Follow-up in a Prospective Gout Cohort
HYUNSUE DO¹, Min Jung Kim², Kichul Shin³ and Ki Won Moon⁴, ¹Kangwon national university hospital, Seoul, South Korea, ²Seoul Metropolitan Government Boramae Medical center, Dongjak-gu, Seoul, South Korea, ³Seoul Metropolitan Government- Seoul National University Boramae Medical Center, Seoul, South Korea, ⁴Kangwon National University hospital, Chuncheon-si, Republic of Korea
Background/Purpose: Gout, a prevalent form of inflammatory arthritis, is generally considered to be easy to manage with urate lowering agent. However, many patients with gout…
Abstract Number: 1109 • ACR Convergence 2024
Differences Between Correlation and Causal Inference in Detecting Predictors of Undefined Crystal Arthropathy in Women
Laura Scagnellato¹, Antonio Collesei², Sonia farah³, Carlomaurizio Montecucco⁴, Francesca Oliviero⁵, Bernd raffeiner⁶, Marta favero⁵, Amelia Damasco⁵, doria Andrea⁵, Fausto Salaffi³ and Roberta Ramonda⁷, and SIR Study Group on Crystal Arthropaties, ¹Rheumatology Unit, University of Padova, Padova, Italy, ²IRCCS Istituto Oncologico Veneto IOV, Padova, Italy, ³Polytechnic University of Marche, Jesi (AN), Italy, ⁴IRCCS policlinico S. Matteo foundation, University of Pavia, Pavia, Italy, ⁵University of Padova, Padova, Italy, ⁶General Hospital of Bolzano, Bolzano, Italy, ⁷Rheumatology Unit, University of Padova, Italy, Padova, Italy
Background/Purpose: Crystal arthropaties, including gout and calcium pyrophosphate deposition disease (CPPD), are prevalent and burdensome conditions. The ALLSTAR model allows the identification of reliable causal,…
Abstract Number: 2011 • ACR Convergence 2024
The Relationship Between Anti-drug Antibodies, Infusion Reactions, and Loss of Urate-lowering Response in Patients with Uncontrolled Gout Treated with Pegloticase
Sanjay Chabra¹, Afroz Mohammad², Katie Obermeyer², Yang Song², Lissa Padnick-Silver², Brian LaMoreaux³ and Peter Lipsky⁴, ¹Texas Arthritis Center, El Paso, TX, ²Amgen, Inc., Thousand Oaks, CA, ³Amgen, Inc., Deerfield, IL, ⁴AMPEL BioSolutions, Charlottesville, VA
Background/Purpose: Immunogenicity of pegloticase, a PEGylated uricase, can limit a sustained urate-lowering response and increase risk for infusion reactions (IRs).1 The MIRROR RCT trial demonstrated…
Abstract Number: 2558 • ACR Convergence 2024
Development of Non-genetic Risk Stratification Model of Severe Allopurinol Hypersensitivity Syndrome, a Multicenter Study in Thailand
Patapong Towiwat¹, Wichittra Tassaneeyakul², Suppachai Lawanaskol³, Chonlaphat Sukasem⁴, Nontaya Nakkam², Ticha Rerkpattanapipat⁴, Jettanong Klaewsongkram⁵, Pawinee Rerknimitr⁵, Duangkamon Poolpun⁶, Worawit Louthrenoo⁷ and Niwat Saksit⁸, ¹Naresuan university, Phitsanulok, Thailand, ²Khon Kaen university, Khon Kaen, Thailand, ³Chaiprakan hospital, Chiang Mai, Thailand, ⁴Mahidol university, Bangkok, Thailand, ⁵Chulalongkorn university, Bangkok, Thailand, ⁶Buddhachinaraj hospital, Phitsanulok, Thailand, ⁷Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand, Chiang Mai, Thailand, ⁸Phayao university, Phayao, Thailand
Background/Purpose: Severe allopurinol hypersensitivity (SAH), although uncommon, is a serious adverse event of allopurinol. Both genetic (HLA-B*58:01) and non-genetic factors (female gender, age ≥60-65 years,…
Abstract Number: 0133 • ACR Convergence 2024
The Association Between Gout and Gallstone Disease: US General Population Analysis
Chio Yokose¹, Bohang Jiang², Natalie McCormick², Sharan Rai² and Hyon K. Choi³, ¹Massachusetts General Hospital, Waltham, MA, ²Massachusetts General Hospital, Boston, MA, ³Massachusetts General Hospital, Lexington, MA
Background/Purpose: Gout is associated with kidney stones, but its association with gallstone disease is not known. Gout and gallstone disease have several shared risk factors…
Abstract Number: 0281 • ACR Convergence 2024
Intra-articular Treatment Combining Sustained Release Colchicine Encapsulated in Microspheres, and Ropivacaine, Is Effective in Inflammatory Arthritis in Rats
Julien GRASSOT¹, Farah MARZOUKI², Roxane HERVE³, Magali BECKLER⁴, Luca SEMERANO⁵, Natacha BESSIS⁶, Elodie RIVIERE⁷, Charles SANSON², Gauthier POULIQUEN², Philippe POULETTY⁸ and Marie-Christophe BOISSIER⁹, ¹PK MED, LYON, Rhone-Alpes, France, ²PK MED, LYON, France, ³INSERM U1125, Bobigny, France, ⁴INSERM 1125, Bobigny, France, ⁵Avicenne Teaching Hospital APHP, Bobigny, France, ⁶INSERM, Université Sorbonne Paris Nord, PARIS, France, ⁷INSERM, Université Sorbonne Paris Nord, APHP, PARIS, France, ⁸PK MED, PARIS, France, ⁹University Sorbonne Paris Nord, Bobigny, France
Background/Purpose: Gout is a common disease with a prevalence and incidence on the rise worldwide. However, approved treatments to treat acute gout flares have slow…
Abstract Number: 1087 • ACR Convergence 2024
Sex Differences in Clinical Features and Mortality in Gout: A Nationwide Retrospective Cohort Study
HYUNSUE DO¹, Kwanyoung Choe², Min Jung Kim³, Kichul Shin⁴ and Ki Won Moon⁵, ¹Kangwon national university hospital, Seoul, South Korea, ²Yeongjusi Health Center, Yeongjusi, Republic of Korea, ³Seoul Metropolitan Government Boramae Medical center, Dongjak-gu, Seoul, South Korea, ⁴Seoul Metropolitan Government- Seoul National University Boramae Medical Center, Seoul, South Korea, ⁵Kangwon National University hospital, Chuncheon-si, Republic of Korea
Background/Purpose: Patients with gout have several coexisting conditions that impact mortality. Studies on clinical features and mortality of female patients with gout are limited, as…
Abstract Number: 1245 • ACR Convergence 2024
Inpatient Discontinuation of Allopurinol – A Quality Improvement (QI) Initiative
Stephanie Tancer¹, Basmah Al Dulaijan² and Puja Khanna³, ¹University of Michigan Department of Internal Medicine, Division of Rheumatology, Ann Arbor, MI, ²Michigan Medicine, Ann Arbor, MI, ³University of Michigan, Ann Arbor, MI
Background/Purpose: Gout is a chronic inflammatory arthritis induced by hyperuricemia and manifested by recurrent acute flares of debilitating joint pain when left untreated. Allopurinol is…

1
2
3
…
45
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].